AAM
SAGE

Alpine Associates Management’s Sage Therapeutics SAGE Stock Holding History

Alpine Associates Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,273,348
Closed -$11.6M – 90
2025
Q2 		$11.6M Buy
+1,273,348
New +$9.37M 0.62% 40

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Alpine Associates Management's SAGE Position: Q3 2025 in Review

Alpine Associates Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 1,273,348 shares — an estimated $11.6M sold.

Alpine Associates Management first reported a position in SAGE in Q2 2025 and held it in 1 quarter. The position peaked at $11.6M in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Alpine Associates Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alpine Associates Management sold 1,273,348 Sage Therapeutics shares in Q3 2025, an estimated $11.6M.
  • Alpine Associates Management first reported a position in Sage Therapeutics in Q2 2025 and held it in 1 quarter.
  • Alpine Associates Management's Sage Therapeutics position peaked at $11.6M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Alpine Associates Management's 13F filing for Q3 2025, filed 6 Nov 2025.